Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Abstract

T-VEC with ipilimumab had a tolerable safety profile, and the combination appeared to have greater efficacy than either T-VEC or ipilimumab monotherapy.

Targeted agents and immunotherapies: optimizing outcomes in melanoma

“…Given the emerging evidence suggesting that the efficacy of anti-PD-1 antibodies is largely confined to patients with tumours that have robust baseline CD8 + T-cell infiltrates 99,100 , T-VEC could potentially be deployed before or concomitantly with immunecheckpoint inhibitors in those with few or no infiltrating T cells at baseline. Of note, preliminary reports have described high response rates in patients with advancedstage melanoma treated using the combination of T-VEC and ipilimumab (~50%) 101 , or pembrolizumab (~46%) 102 ; a phase III trial of pembrolizumab with and without T-VEC is underway (NCT02263508).…”

Treatment of advanced melanoma - A changing landscape

“…T-VEC in association with ipilimumab produced an ORR of 50%, with 44% of the patients having durable responses of at least 6 months; the 18-month overall survival was 67%. 47 The combination of TVEC with pembrolizumab achieved an ORR of 57.1%, with 23.8% having confirmed complete responses. This strategy is now being further evaluated in an ongoing phase 3 clinical trial (MASTERKEY265; NCT02263508).…”

From chemotherapy to oncoviruses – modern methods of treatment in metastatic melanoma

“…Subsequently, those presenting cells activate a response of T-cells to melanoma cells. Deletion of two insignificant genes, infected cell protein 34.5 (ICP34.5) and ICP47, diminishes viral neuropathogenicity and promotes preferential replication within tumor cells [35][36][37][38][39][40] (Fig. 1).…”

“…Subjects were randomized and received an intralesional injection of T-VEC (initial dose of 10 6 plaque-forming units (PFU)/ml, followed 3 weeks later by 10 8 PFU/ml and continued every 2 weeks for 12-18 months) or subcutaneous recombinant GM-CSF (125 μg daily for 14 days in a 28-day cycle for 12-18 months) [35,37,40]. More than half (55%) of the patients had not received prior therapy at baseline [37].…”